ICD-10-CM Billable Code

C81.07

Nodular lymphocyte predominant Hodgkin lymphoma, spleen

Clinical Classification Guidelines

Medical Intelligence & Overview

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare type of Hodgkin lymphoma, a cancer that originates in the lymphatic system. When this disease affects the spleen, it is specifically classified under the ICD-10 code C81.07. The spleen, an organ involved in filtering blood and supporting the immune system, can become enlarged and affected by this form of lymphoma, influencing various bodily functions.

Causes & Symptoms

Clinical Causes: Genetic mutations that affect lymphocytes Infections, particularly with Epstein-Barr Virus (EBV), though this is less common compared to other types of lymphoma Immune system dysregulation, which may contribute to abnormal lymphocyte growth Environmental factors, although specific external causes are not well established

Key Symptoms: Enlarged spleen (splenomegaly), which can cause discomfort or pain in the upper abdomen Swelling of lymph nodes in the neck, armpits, or groin Unexplained weight loss Fever that persists or recurs Night sweats Fatigue or general weakness Frequent infections due to immune system impairment Unexplained anemia or bleeding tendencies

Diagnostic & Treatment

Diagnosis Path: To diagnose nodular lymphocyte-predominant Hodgkin lymphoma of the spleen, doctors may use a combination of tests and procedures, including: - Physical examination focusing on enlarged lymph nodes and spleen - Blood tests to evaluate blood cell counts and overall health - Imaging techniques such as ultrasound, CT scan, or MRI to visualize spleen and lymph nodes - Biopsy of spleen tissue or lymph node to confirm lymphoma type - Immunohistochemistry and molecular studies to identify specific lymphoma markers Accurate diagnosis often requires tissue analysis under the microscope, emphasizing the importance of biopsy procedures.

Treatment Protocols: Treatment options depend on the disease stage and patient health and may include: - Chemotherapy to target cancerous lymphocytes - Immunotherapy to boost the body's ability to fight the lymphoma - Radiation therapy in certain cases to destroy localized cancer cells - Surgical removal of the spleen (splenectomy) in some conditions, though this is less common - Targeted therapies designed for specific molecular features of the lymphoma Because NHLPL affecting the spleen is a rare condition, management is usually coordinated by a team of specialists such as hematologists and oncologists, tailored to individual patient needs.

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is C81.07 a billable ICD-10 code?
Yes, C81.07 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report C81.07?
Clinical documentation must specify the nature of Nodular lymphocyte predominant Hodgkin lymphoma, spleen and any associated comorbidities for accurate reporting.

Cite this Clinical Reference

Clinical Meta Tags

lymphocyte predominant hodgkin nodular spleen